Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Current Report)
Date of Report: May 9, 2013
Context: The Company filed a Japanese report ("Kessan Tanshin") with the Osaka Securities Exchange containing financial results for the quarter ended March 31, 2013, and forward-looking financial forecasts. This 8-K serves as Regulation FD disclosure of that information.
Key Financial Metrics and Guidance
The filing provides specific financial forecasts for the six months ending June 30, 2013, and the full year ending December 31, 2013. Historical results for the quarter ended March 31, 2013, are referenced but not detailed in this specific text.
| Period | Revenues | Operating Loss | Net Loss | Loss Per Share (Basic & Diluted) |
|---|---|---|---|---|
| Six months ending June 30, 2013 | $3,257 | $5,147,000 | $5,149,000 | $0.26 |
| Year ending December 31, 2013 | $650,000 | $9,921,000 | $9,921,000 | $0.50 |
Note: Loss per share calculations assume a weighted average of 20,000,000 shares. The filing does not provide specific data on cash flow, debt, or liquidity metrics for the current period.
Material Changes and Unusual Items
The filing does not explicitly detail material changes in revenue or profit compared to the prior comparable period, as the primary focus is the disclosure of the Japanese report and future forecasts. The text notes that financial statements denominated in Japanese yen are disclosed as supplementary information in the Tanshin, translated at a rate of 97.92 Japanese yen per U.S. dollar (as of April 30, 2013).
Outlook, Risks, and Management Commentary
Management Commentary: The forecasts are based on management's assumptions regarding current conditions and trends. Management believes these assumptions are reasonable but cannot assure that actual results will align with estimates.
Risks and Contingencies: The filing highlights significant risks that could cause actual results to differ materially from forecasts, including:
- Risks inherent in clinical trials, product development, and commercialization.
- Uncertainty regarding regulatory approval and the predictive nature of clinical trial results.
- Reliance on third parties for clinical trials and manufacturing.
- Potential delays or increased costs in clinical trial enrollment and analysis.
- Risks related to a joint venture in China and collaborations with third parties.
- Availability of funds to complete product development and the ability to raise sufficient capital.
Auditor Note: Independent auditors have not compiled or been involved in the preparation of the forecasted financial results and assume no responsibility for their accuracy.
Investor Verification Checklist
- Verify the actual financial results for the quarter ended March 31, 2013, by reviewing the referenced Form 10-Q, as this 8-K only summarizes the Japanese filing.
- Confirm the weighted average number of shares outstanding, as the forecasted EPS relies on an assumed 20,000,000 shares.
- Review the Company's Annual Report on Form 10-K for the year ended December 31, 2012, for detailed risk factors.
- Monitor the status of the joint venture in China and ongoing clinical trials, as these are cited as key variables affecting future performance.
- Assess the Company's capital position and ability to raise funds, given the projected net losses for the remainder of 2013.